198 related articles for article (PubMed ID: 15842657)
1. Fusion hybrids of dendritic cells and autologous myeloid blasts as a potential cellular vaccine for acute myeloid leukaemia.
Klammer M; Waterfall M; Samuel K; Turner ML; Roddie PH
Br J Haematol; 2005 May; 129(3):340-9. PubMed ID: 15842657
[TBL] [Abstract][Full Text] [Related]
2. Dendritic cells fused with core binding factor-beta positive acute myeloid leukaemia blast cells induce activation of cytotoxic lymphocytes.
Banat GA; Usluoglu N; Hoeck M; Ihlow K; Hoppmann S; Pralle H
Br J Haematol; 2004 Aug; 126(4):593-601. PubMed ID: 15287954
[TBL] [Abstract][Full Text] [Related]
3. Leukemia-derived dendritic cells can be generated from blood or bone marrow cells from patients with acute myeloid leukaemia: a methodological approach under serum-free culture conditions.
Kufner S; Zitzelsberger H; Kroell T; Pelka-Fleischer R; Salem A; de Valle F; Schweiger C; Nuessler V; Schmid C; Kolb HJ; Schmetzer HM
Scand J Immunol; 2005 Jul; 62(1):86-98. PubMed ID: 16091128
[TBL] [Abstract][Full Text] [Related]
4. Induction of leukemia-specific cytotoxic response by cross-presentation of late-apoptotic leukemic blasts by autologous dendritic cells of nonleukemic origin.
Spisek R; Chevallier P; Morineau N; Milpied N; Avet-Loiseau H; Harousseau JL; Meflah K; Gregoire M
Cancer Res; 2002 May; 62(10):2861-8. PubMed ID: 12019165
[TBL] [Abstract][Full Text] [Related]
5. Quality of T-cells after stimulation with leukemia-derived dendritic cells (DC) from patients with acute myeloid leukemia (AML) or myeloid dysplastic syndrome (MDS) is predictive for their leukemia cytotoxic potential.
Liepert A; Grabrucker C; Kremser A; Dreyssig J; Ansprenger C; Freudenreich M; Kroell T; Reibke R; Tischer J; Schweiger C; Schmid C; Kolb HJ; Schmetzer H
Cell Immunol; 2010; 265(1):23-30. PubMed ID: 20663492
[TBL] [Abstract][Full Text] [Related]
6. Dendritic cell-based immunotherapy in myeloid leukaemia: translating fundamental mechanisms into clinical applications.
van de Loosdrecht AA; van den Ancker W; Houtenbos I; Ossenkoppele GJ; Westers TM
Handb Exp Pharmacol; 2009; (188):319-48. PubMed ID: 19031033
[TBL] [Abstract][Full Text] [Related]
7. Stimulating capacity of blast cells from patients with chronic myelocytic leukaemia, in blastic crisis in 'one-way' mixed lymphoycte reaction: lack of evidence for T lymphoblastic conversion.
Han T; Gomez GA; Minowada J
Immunology; 1978 Aug; 35(2):299-305. PubMed ID: 155646
[TBL] [Abstract][Full Text] [Related]
8. Tumour cell/dendritic cell fusions as a vaccination strategy for multiple myeloma.
Raje N; Hideshima T; Davies FE; Chauhan D; Treon SP; Young G; Tai YT; Avigan D; Gong J; Schlossman RL; Richardson P; Kufe DW; Anderson KC
Br J Haematol; 2004 May; 125(3):343-52. PubMed ID: 15086415
[TBL] [Abstract][Full Text] [Related]
9. Activation of autologous leukemia-specific T cells in acute myeloid leukemia: monocyte-derived dendritic cells cocultured with leukemic blasts compared with leukemia-derived dendritic cells.
Draube A; Beyer M; Wolf J
Eur J Haematol; 2008 Oct; 81(4):281-8. PubMed ID: 18573171
[TBL] [Abstract][Full Text] [Related]
10. Vaccination with autologous non-irradiated dendritic cells in patients with bcr/abl+ chronic myeloid leukaemia.
Westermann J; Kopp J; van Lessen A; Hecker AC; Baskaynak G; le Coutre P; Döhner K; Döhner H; Dörken B; Pezzutto A
Br J Haematol; 2007 May; 137(4):297-306. PubMed ID: 17408402
[TBL] [Abstract][Full Text] [Related]
11. Dendritic cell-tumor cell hybrids enhance the induction of cytotoxic T lymphocytes against murine colon cancer: a comparative analysis of antigen loading methods for the vaccination of immunotherapeutic dendritic cells.
Yasuda T; Kamigaki T; Nakamura T; Imanishi T; Hayashi S; Kawasaki K; Takase S; Ajiki T; Kuroda Y
Oncol Rep; 2006 Dec; 16(6):1317-24. PubMed ID: 17089056
[TBL] [Abstract][Full Text] [Related]
12. [Induction of efficient T-cell immunity against autologous leukemia cells by dendritic cells pulsed with the leukemia cell total RNA].
Ge W; You SG; Wang YF; Li CH; Liu XF; He XP; Ma S; Qiu L
Zhonghua Xue Ye Xue Za Zhi; 2005 Aug; 26(8):461-4. PubMed ID: 16383235
[TBL] [Abstract][Full Text] [Related]
13. Phase I/II study of vaccination with dendritic-like leukaemia cells for the immunotherapy of acute myeloid leukaemia.
Roddie H; Klammer M; Thomas C; Thomson R; Atkinson A; Sproul A; Waterfall M; Samuel K; Yin J; Johnson P; Turner M
Br J Haematol; 2006 Apr; 133(2):152-7. PubMed ID: 16611305
[TBL] [Abstract][Full Text] [Related]
14. Clinical-grade manufacturing of autologous mature mRNA-electroporated dendritic cells and safety testing in acute myeloid leukemia patients in a phase I dose-escalation clinical trial.
Van Driessche A; Van de Velde AL; Nijs G; Braeckman T; Stein B; De Vries JM; Berneman ZN; Van Tendeloo VF
Cytotherapy; 2009; 11(5):653-68. PubMed ID: 19530029
[TBL] [Abstract][Full Text] [Related]
15. Dendritic cells loaded with apoptotic tumour cells induce a stronger T-cell response than dendritic cell-tumour hybrids in B-CLL.
Kokhaei P; Rezvany MR; Virving L; Choudhury A; Rabbani H; Osterborg A; Mellstedt H
Leukemia; 2003 May; 17(5):894-9. PubMed ID: 12750703
[TBL] [Abstract][Full Text] [Related]
16. Acute myelogenous leukemia blasts as accessory cells during in vitro T lymphocyte activation.
Bruserud O; Ulvestad E
Cell Immunol; 2000 Nov; 206(1):36-50. PubMed ID: 11161436
[TBL] [Abstract][Full Text] [Related]
17. Generation of T-cell lines to autologous acute myeloid leukemia cells by competitive limiting dilution culture of acute myeloid leukemia mononuclear cells.
Zhong RK; Lane TA; Ball ED
Exp Hematol; 2008 Apr; 36(4):486-94. PubMed ID: 18249062
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy for patients with acute myeloid leukemia using autologous dendritic cells generated from leukemic blasts.
Li L; Giannopoulos K; Reinhardt P; Tabarkiewicz J; Schmitt A; Greiner J; Rolinski J; Hus I; Dmoszynska A; Wiesneth M; Schmitt M
Int J Oncol; 2006 Apr; 28(4):855-61. PubMed ID: 16525634
[TBL] [Abstract][Full Text] [Related]
19. Transduction of acute myeloid leukemia cells with third generation self-inactivating lentiviral vectors expressing CD80 and GM-CSF: effects on proliferation, differentiation, and stimulation of allogeneic and autologous anti-leukemia immune responses.
Koya RC; Kasahara N; Pullarkat V; Levine AM; Stripecke R
Leukemia; 2002 Sep; 16(9):1645-54. PubMed ID: 12200676
[TBL] [Abstract][Full Text] [Related]
20. Leukemia-specific T-cell reactivity induced by leukemic dendritic cells is augmented by 4-1BB targeting.
Houtenbos I; Westers TM; Dijkhuis A; de Gruijl TD; Ossenkoppele GJ; van de Loosdrecht AA
Clin Cancer Res; 2007 Jan; 13(1):307-15. PubMed ID: 17170077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
